Parker Waichman LLP

Report: Diabetes Drugs Associated with Elevated Cancer Risks

A number of diabetes medications, including Byetta and Januvia, are being probed by the U.S. Food and Drug Administration (FDA) over links to pancreatic cancer. Diabetes drugs manufactured by Merck & Company Inc., AstraZeneca PLC, and other drug makers are involved over claims that their drugs, when compared to other diabetes drugs, are 25 times […]

A number of diabetes medications, including Byetta and Januvia, are being probed by the U.S. Food and Drug Administration (FDA) over links to pancreatic cancer.

Diabetes drugs manufactured by Merck & Company Inc., AstraZeneca PLC, and other drug makers are involved over claims that their drugs, when compared to other diabetes drugs, are 25 times likelier to increase pancreatic cancer rates, said Law360. Watchdog group, the Institute for Safe Medication Practices (ISMP) reviewed a year of adverse event reports made to the FDA related to five Type 2 diabetes medications, including Januvia, manufactured by Merck; Byetta, manufactured by AstraZeneca and Bristol-Myers Squibb Co.; and Tradjenta, made by Eli Lilly & Co., said Law360.

The research revealed, said ISMP, 105 cases of pancreatic cancer reported in patients taking these drugs compared to two cases in a different diabetes drug class. Two injectable medications were found to be 28 times likelier to be linked to pancreatitis; three oral drugs were 20 times likelier to be linked to the same condition, said the ISMP, according to Law360. “These data and other recent studies establish the need to reassess the safety of this class of drugs,” the ISMP said.

This March, the FDA initiated a probe based on a medical journal study that revealed the drugs, in a class known as incretin mimetics, may lead to an increased risk of pancreatitis and precancerous cellular changes (pancreatic duct metaplasia), said Law360. The European Medicines Agency (EMA), Europe’s top drug watchdog group initiated its own recommendation following the FDA’s probe.

Incretin mimetic drugs include Byetta and Bydureon (exenatide); Victoza (liraglutide); Januvia, Janumet, Janumet XR, and Juvisync (sitagliptin); Onglyza and Kombiglyze XR (saxagliptin); Nesina, Kazano, and Oseni (alogliptin); and Tradjenta and Jentadueto (linagliptin). These drugs increase certain natural substances that lower raised blood sugar levels. Diabetics typically have abnormally low insulin levels or their bodies have difficulties utilizing insulin efficiently.

Incretin mimetic drugs imitate the body’s incretin hormones. These hormones are meant to stimulate insulin release following consumption of meals and are typically used in collaboration with diet and exercise to lower blood sugar in adults diagnosed with Type 2 diabetes. In 2009, the FDA required a label update on these drugs warning of the risk of acute pancreatitis, a painful, potentially fatal disorder and a known risk factor for pancreatic cancer.

Pancreatitis is an inflammation of the pancreas that is linked to cancer and kidney failure. Chronic pancreatitis is painful, potentially fatal, and a known risk factor for pancreatic cancer. The serious side effects linked to these Type 2 diabetes drugs, include low blood sugar; anaphylaxis and other allergic reactions, such as hives, rash, swelling of the face, lips, tongue, and/or throat; diseases of the pancreas such as acute, necrotizing, or hemorrhagic pancreatitis; pancreatic cancer; thyroid cancer; vomiting and nausea; anorexia; persistent, severe abdominal pain, sometimes radiating to the back; and death.

The ISMP did point out that a drug being mentioned on an FDA adverse event report does not mean that the drug directly causes a condition; however, “onsidered as a group, these data provide a signal for pancreatic cancer substantial enough to warrant further investigation,” the group said. The group did recommend the FDA increase prescribing information for incretin mimetics, according to Law 360.

Merck has been targeted in a wrongful death lawsuit being heard in Illinois state court this March that alleges three people developed pancreatic cancer due to their taking Januvia. Plaintiffs in those lawsuits claim that Januvia has a defective design and lacks adequate warnings about its alleged association with a significantly increased risk of developing pancreatic cancer, said Law360.

Prior research also revealed that Januvia and Byetta have been associated with reports of increased risks for pancreatic and thyroid cancers. Another new study also found that the drugs may double patients’ risks for developing pancreatitis, the first time a study put a number to the risk. In the United States, about 8.6 percent of the population—25 million people—were diagnosed with diabetes in 2010, based on prior Bloomberg News data. That number is expected to rise to more than 34 million by 2020.

What Our Clients Say About Us
We have worked with thousands of clients and we appreciate them and their positive reviews. Here are just a few recent client reviews...
5 Star Reviews 150
PW is top notch. I felt perfectly comfortable with the staff and the in person visit with the paralegal was excellent she explained everything to me in a knowledgeable fashion. I would highly recommend PW.
Vikki Mclaurin
10 months ago
5 Star Reviews 150
Thank you very much for helping me get my money but special thanks to Jorge who was always ready to help me with my case, sorry I must make a strong criticism of Michael who never helped me and complicated the process for me, I think he no longer works with this office, thank you Mil Jorge I will give you 5 and up to 20 stars for your work
Alvaro Sanchez
6 months ago
5 Star Reviews 150
Thank you Parker Waichman LLP and especially paralegal Benita Rollis who guided me through the whole process. She was very professional, courteous and always called me back when I had any questions. I was very satisfied and highly recommend Parker Waichman LLP.
Denise Saraceno
2 years ago

Why Choose Us to Help You?

We Take Care of Everything
Your situation is stressful enough: Let us take on the deadlines, paperwork, investigation, and litigation. We'll handle every detail so you don't have to worry.
No Recovery = No Legal Fees
We work on a contingency-fee basis, meaning that we only get paid from a portion of your settlement or jury award. If you don't get compensation, you owe us nothing.
Decades of Experience
Your situation is stressful enough: Let us take on the deadlines, paperwork, investigation, and litigation. We'll handle every detail so you don't have to worry.
Respected by Our Peers
Judges, insurance adjusters, and fellow attorneys all speak highly of our skills, and we've earned numerous accolades, including a flawless rating from AVVO.
We Have Many Locations To Serve You
We have the experience and the skilled litigators to win your case. Contact us and speak with a real attorney who can help you.
Long Island – Nassau
Parker Waichman LLP
6 Harbor Park Drive
Port Washington, NY 11050
Long Island – Suffolk
Parker Waichman LLP
201 Old Country Road – Suite 145
Melville, NY 11747
New York
Parker Waichman LLP
59 Maiden Lane, 6th Floor
New York, NY 10038
Queens
Parker Waichman LLP
118-35 Queens Boulevard, Suite 400
Forest Hills, NY 11375
Brooklyn
Parker Waichman LLP
300 Cadman Plaza West
One Pierrepont Plaza, 12th Floor
Brooklyn, NY 11201
New Jersey
Parker Waichman LLP
80 Main Street, Suite 265
West Orange, NJ 07052
Florida
Parker Waichman LLP
27299 Riverview Center Boulevard
Suite 108
Bonita Springs, FL 34134
Nationwide Service
Parker Waichman LLP
59 Maiden Lane, 6th Floor
New York, NY 10038